Mitochondrial biomarkers for parkinson’s disease early diagnosis
A research initiative to identify mitochondrial biomarkers for Parkinson's Disease (PD) by examining delayed mitophagy and Miro1 retention in various cell types. This study aims to enhance early diagnosis and pave the way for personalized therapies.
Overview
This research initiative explores the potential of mitochondrial biomarkers for early diagnosis of Parkinson's Disease (PD). By investigating delayed mitophagy and the retention of the mitochondrial protein Miro1 in peripheral blood mononuclear cells (PBMCs), fibroblasts, induced pluripotent stem cells (iPSCs), and extracellular vesicles (EVs), the study seeks to establish a reliable diagnostic tool. Identifying mitophagy impairment, a phenotype specific to PD, could lead to earlier and more accurate diagnoses, ultimately facilitating personalized therapy options.
Technical specifications
- Delayed Mitophagy Measurement: Quantification of mitophagy levels in PBMCs, fibroblasts, iPSCs, and EVs from PD patients compared to healthy controls.
- Miro1 Retention Analysis: Investigation of the correlation between Miro1 retention and mitophagy impairment using high throughput Western Blotting.
- Mechanistic Studies and Compound Screening: Screening of compounds that target upstream causes of Miro1 retention, using high-throughput live cell imaging with Leica Stellaris 8 confocal microscopy.
- Future Validation: Optimization of live cell imaging conditions and algorithms for tracking mitophagy, validation of findings across various biomaterials, and testing of therapeutic compounds.
Technology readiness level
Currently, this research is at Technology Readiness Level 2, with ongoing efforts to validate biomarkers and develop diagnostic tools through advanced imaging and compound testing.
About University of Tübingen
Eberhard Karls University of Tübingen is a large, comprehensive public research university in Baden‑Württemberg with a global outlook and a strong record of basic and translational discovery. Its integration with a major university hospital supports clinical research and translation at scale. Co‑located national research institutes and a vibrant regional innovation ecosystem enable joint labs, shared facilities, and industry‑sponsored collaborations, while proximity to Stuttgart’s manufacturing and mobility hub facilitates pilot testing and scale‑up. Research is supported by competitive funding from the German Research Foundation, the Federal Ministry of Education and Research, and European Union programs. A dedicated technology transfer office manages IP, licensing, startup formation, and streamlined contracting for corporate R&D.
Inquire about this partnering listing
Industry applications
delivered to your inbox.